BioMimetic Therapeutics to Report 2008 Fourth Quarter and Year End Financial Results on March 12; Company to Host Conference Call March 13
Franklin, Tenn. – March 11, 2009 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company plans to release its financial results for the twelve months ended December 31, 2008, on Thursday, March 12, 2009 after the close of the market. The Company will host a conference call and audio webcast to discuss its fourth quarter and year-end financial results and product development programs and business activities at 8:30 ET the next morning, March 13.
The conference call may be accessed on March 13, 2009 by dialing 888.680.0878 (passcode: 97841529). The international dial in number is 617.213.4855, and the same passcode applies. You may also pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=P4KELXJM9.
A live webcast of the conference call will be available on the Investor Relations section of BioMimetic's website at www.biomimetics.com. The webcast will be archived for at least 30 days following the call.
About BioMimetic Therapeutics
BioMimetic Therapeutics, Inc. is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product, GEM 21S®, as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of the rhPDGF-BB platform technology. Additionally, the Company has clinical trials ongoing with its product candidates Augment and Augment Injectable in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the wrist. The Company's previously approved product and lead product candidates all combine recombinant protein therapeutics (rhPDGF-BB) with tissue specific scaffolds to actively stimulate tissue healing and regeneration.
GEM 21S® is the registered trademark of Luitpold Pharmaceuticals, Inc., who now owns and markets that product.
For further information, visit www.biomimetics.com or contact Kearstin Patterson, corporate communications, at 615-236-4419.
Back to Headlines |
